Status:
UNKNOWN
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars
Lead Sponsor:
RXi Pharmaceuticals, Corp.
Conditions:
Hypertrophic Scar
Eligibility:
All Genders
21-55 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic scar.
Eligibility Criteria
Inclusion
- Adults, 21-55 years of age
- General good health
- Previous surgery or injury resulting in a hypertrophic scar
Exclusion
- Scars on the face or front of neck may not be included in the trial
- Use of tobacco or nicotine-containing products
- Pregnant or lactating
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2018
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT02246465
Start Date
July 1 2014
End Date
March 1 2018
Last Update
February 23 2018
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Beverly Hills, California, United States, 90210
2
Lake Worth, Florida, United States, 33461
3
Chicago, Illinois, United States, 60611
4
St Louis, Missouri, United States, 63141